Smith & Nephew (LON:SN) Shares Cross Above Two Hundred Day Moving Average – What’s Next?

Smith & Nephew plc (LON:SN) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of GBX 1,303.12 and traded as high as GBX 1,348. Smith & Nephew shares last traded at GBX 1,336.50, with a volume of 1,682,716 shares changing hands.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Citigroup upped their price target on shares of Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the stock a “buy” rating in a research report on Friday, October 31st. Panmure Gordon reiterated a “hold” rating and set a GBX 1,200 price objective on shares of Smith & Nephew in a research note on Tuesday, December 9th. Royal Bank Of Canada cut Smith & Nephew to a “sector perform” rating and reduced their target price for the company from GBX 1,700 to GBX 1,350 in a report on Wednesday, December 17th. Berenberg Bank reaffirmed a “hold” rating and issued a GBX 1,300 price target on shares of Smith & Nephew in a research note on Friday, January 23rd. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Smith & Nephew in a research report on Friday, November 7th. Two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Smith & Nephew has a consensus rating of “Hold” and an average price target of GBX 1,381.33.

Smith & Nephew Price Performance

The firm has a market capitalization of £14.65 billion, a PE ratio of 48.12, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62. The stock’s 50 day simple moving average is GBX 1,249.08 and its two-hundred day simple moving average is GBX 1,303.12. The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.